Caribou Biosciences (CRBU) Assets Average (2021 - 2026)

Caribou Biosciences (CRBU) has 6 years of Assets Average data on file, last reported at $162.2 million in Q1 2026.

• Quarterly Assets Average fell 44.74% year-over-year to $162.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $162.2 million (down 44.74% YoY) and the FY2025 annual result came in at $244.3 million, down 34.45% from the prior year.
• Assets Average retreated to $162.2 million in Q1 2026 per CRBU's latest filing, from $185.2 million in the prior quarter.
• Across five years, Assets Average topped out at $444.9 million in Q4 2023 and bottomed at $162.2 million in Q1 2026.
• The 5-year median for Assets Average is $360.6 million (2023), against an average of $342.6 million.
• The widest annual swing landed in 2022, when Assets Average surged 32.21%; it then plunged 44.74% in 2026.
• Tracing CRBU's Assets Average over 5 years: stood at $386.3 million in 2022, then rose by 15.16% to $444.9 million in 2023, then retreated by 26.08% to $328.8 million in 2024, then sank by 43.69% to $185.2 million in 2025, then dropped by 12.42% to $162.2 million in 2026.
• Per Business Quant, the three latest CRBU Assets Average figures stand at $162.2 million (Q1 2026), $185.2 million (Q4 2025), and $207.9 million (Q3 2025).

Peer Comparison